Press release
October 22, 2026
Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Acumen Pharmaceuticals, Inc. (ABOS)
We couldn't retrieve the full text for this release. Read it on the company's site.